This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Neuralstem To Present Preclinical Data At Neuroscience 2012, 42nd Annual Meeting Of The Society For Neuroscience

ROCKVILLE, Md., Oct. 10, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it will present preclinical data in five poster presentations at Neuroscience 2012, the 42 nd Annual Meeting for the Society for Neuroscience., October 13-17, in New Orleans ( http://www.sfn.org/AM2012/). These posters will cover new data pertaining to Neuralstem's NSI-566 spinal cord stem cell line for cell therapy, and its patented, neurogenic small molecule compounds: NSI-144, NSI-150, NSI-158 and NSI-189. Abstracts of the poster are available at http://www.sfn.org/am2012/index.aspx?pagename=final_program

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

NSI-566 is in a Phase I trial to test the safety of the cells and procedure in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The last patient was treated in August, 2012. Neuralstem was recently approved to commence a NSI-566 trial in stroke in China, through its Chinese subsidiary, Neuralstem China, and has submitted an IND to the FDA to commence a trial in spinal cord injury with the same cells in the U.S.

NSI-144, NSI-150, NSI-158 and NSI-189 are small molecule, orally active compounds that stimulate new neuron growth in the hippocampus. NSI-189 is currently in a Phase Ib clinical trial testing its safety for the treatment of major depressive disorder (MDD).

The titles and schedule for Neuralstem's poster presentations at Neuroscience 2012 are:

NSI-566

  • "Survival and Differentiation of Human Neural Stem Cells (NSI-566RSC) After Grafting into Ischemia-Injured Porcine Brain," S.Wu et. al., University of California, San Diego, Poster #59.14/L20 - Saturday, October 13, 2:00-3:00, Hall F-J  
  • "Histopathological Assessment of Adult Ischemic Rat Brains After Intracerebral Transplantation of NSI-566RSC Cell Line," K.L. Hayama et. al., University of South Florida, Poster # 59.15/M1 - Saturday, October 13, 3:00-4:00, Hall F-J
  • "Decreased Tau Phosphorylation by AMPK Activation in Cortical Neurons," B. Kim et. al., University of Michigan, Poster # 220.08 - Sunday, October 14, 2:45-3:00, Location: 395 
  • "A Study to Examine the Tumorgenicity of Human Neural Stem Cell Line NSI-566RSC in Spinal Cord Injured Rats," T. Lam et. al., University of California, San Diego, Poster #450.17/K7 - Monday, October 15, 1:00-2:00. Hall F-J

NSI-144, NSI-150, NSI-158 and NSI-189

  • "Histological Assessment of Mouse Brains After 28-Day Chronic Oral Administration of Four Novel Neurogenic Compounds," D. Lee et. al, Poster # 664.20/X1 - Tuesday, October 16, 4:00 – 6:00, Hall F-J.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently treated the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,115.79 +9.09 0.05%
S&P 500 2,000.83 +0.81 0.04%
NASDAQ 4,572.25 +1.6130 0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs